Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells

被引:42
作者
Emaduddin, Muhammad [1 ]
Bicknell, David C. [2 ]
Bodmer, Walter F. [2 ]
Feller, Stephan M. [1 ]
机构
[1] John Radcliffe Hosp, Cell Signalling Grp, Oxford OX3 9DS, England
[2] John Radcliffe Hosp, Canc & Immunogenet Grp, Weatherall Inst Mol Med, Oxford OX3 9DS, England
关键词
colon; therapy; kinase inhibition; molecular heterogeneity;
D O I
10.1073/pnas.0712176105
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The heterogeneity of cancer cell signaling is a significant obstacle for the effective development and clinical use of molecularly targeted therapies. As a contribution to a better understanding of the diversity of signaling activities in colorectal cancers (CRCs), we have analyzed the activity of Src family kinases (SFKs), which are implicated in human cancer development, in 64 CRC cell lines. A striking diversity of SFK activity was observed within this panel. Importantly, all CRC lines tested depend on SFK activity for their growth. In addition, SFK activity levels strongly correlated with global levels of tyrosine-phosphorylated (pTyr) proteins in CRC lines. SFK inhibition substantially reduced these pTyr levels, suggesting that SFKs may function as signal integration points and master controllers for the pTyr protein status in CRC lines. The majority of analyzed CRC lines with high-SFK activity express activated c-Met (pYpY1234/1235), a receptor tyrosine kinase contributing to the regulation of cell proliferation, migration, and invasion. Inhibition of SFKs reduced c-Met phosphorylation in most cases, indicating a reversed signal flow from SFK to c-Met. We conclude that SFK activity is important for the growth of CRC lines, although only low activity levels are required. If this also is true for CRC patients, tumors with low-SFK activity may be particularly sensitive to SFK inhibitors, and such patients should be targeted in clinical trials testing SFK inhibitors.
引用
收藏
页码:2358 / 2362
页数:5
相关论文
共 32 条
[1]   Activation of Src kinase in primary colorectal carcinoma - An indicator of poor clinical prognosis [J].
Allgayer, H ;
Boyd, DD ;
Heiss, MM ;
Abdalla, EK ;
Curley, SA ;
Gallick, GE .
CANCER, 2002, 94 (02) :344-351
[2]   The specificities of protein kinase inhibitors: an update [J].
Bain, J ;
McLauchlan, H ;
Elliott, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2003, 371 :199-204
[3]   Met, metastasis, motility and more [J].
Birchmeier, C ;
Birchmeier, W ;
Gherardi, E ;
Vande Woude, GF .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) :915-925
[4]   Cancer genetics: colorectal cancer as a model [J].
Bodmer, WF .
JOURNAL OF HUMAN GENETICS, 2006, 51 (05) :391-396
[5]  
BODMER WF, 1996, J R COLL PHYSICIANS, V31, P82
[6]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[7]   TISSUE TYPING THE HLA-A LOCUS FROM GENOMIC DNA BY SEQUENCE-SPECIFIC PCR - COMPARISON OF HLA GENOTYPE AND SURFACE EXPRESSION ON COLORECTAL TUMOR-CELL LINES [J].
BROWNING, MJ ;
KRAUSA, P ;
ROWAN, A ;
BICKNELL, DC ;
BODMER, JG ;
BODMER, WF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (07) :2842-2845
[8]   Role of β-arrestin 1 in the metastatic progression of colorectal cancer [J].
Buchanan, FG ;
Gorden, DL ;
Matta, P ;
Shi, Q ;
Matrisian, LM ;
DuBois, RN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (05) :1492-1497
[9]   DIFFERENTIAL REGULATION OF T-CELL ANTIGEN RESPONSIVENESS BY ISOFORMS OF THE SRC-RELATED TYROSINE PROTEIN-KINASE P59FYN [J].
DAVIDSON, D ;
CHOW, LML ;
FOURNEL, M ;
VEILLETTE, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (06) :1483-1492
[10]   A GENETIC MODEL FOR COLORECTAL TUMORIGENESIS [J].
FEARON, ER ;
VOGELSTEIN, B .
CELL, 1990, 61 (05) :759-767